Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics reported $21.0 million collaboration revenue in the second quarter of 2026 from selling its IFNα 898 Program to Jazz Pharmaceuticals, producing quarterly net income of $3.7 million after a prior-year loss. For the first half of 2026, the company still recorded a net loss of $9.9 million as R&D fell to $14.3 million and G&A rose to $12.8 million, reflecting a sharp pullback in development spending and higher advisory and legal costs tied to a strategic review.
Werewolf ended June 30, 2026 with $22.0 million in cash and cash equivalents and has fully repaid its $30.0 million K2 HealthVentures term loan via a $31.4 million payment, eliminating secured debt but triggering a $3.4 million extinguishment loss. Management discloses “substantial doubt” about the ability to continue as a going concern for at least twelve months and is exploring strategic alternatives, including a sale or partnerships, while executing a 2026 restructuring with major workforce reductions and an expected $6.5 million in total restructuring costs. Lead oncology programs WTX-124 and WTX-330 remain in early-stage trials targeted to complete in the fourth quarter of 2026, but further development will require additional funding or partners.
Werewolf Therapeutics, Inc. reported second quarter 2026 results highlighted by a shift to profitability and a major asset transaction. The company entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited for its JZP898 program and repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC. These transactions included a $21.0 million payment to Werewolf and support ongoing evaluation of strategic alternatives with financial advisor Piper Sandler.
For the quarter ended June 30, 2026, collaboration revenue was $21.0 million, research and development expenses were $6.2 million versus $13.1 million a year earlier, and general and administrative expenses were $7.7 million versus $4.4 million. Net income was $3.7 million, compared with a net loss of $18.0 million in the prior-year period. As of June 30, 2026, cash and cash equivalents were $22.0 million, compared with $46.5 million as of March 31, 2026, and management expects existing cash to fund operations into the second quarter of 2027 while advancing INDUKINE and INDUCER pipeline programs, including WTX-124 and WTX-330.
Werewolf Therapeutics director Luke Evnin reported indirect open-market sales of 143,199 shares of Common Stock over two days. On July 6, 2026, entities associated with him sold 35,770 shares at a weighted average price of $0.32 per share. On July 7, 2026, they sold a further 107,429 shares at a weighted average price of $0.31 per share.
The trades were executed by multiple MPM-affiliated investment entities and carried out under a pre-established Rule 10b5-1 trading plan dated March 26, 2026. Following these transactions, those entities reported holding no shares of Werewolf Therapeutics.
RA Capital Management and affiliated funds filed Amendment No. 12 to their Schedule 13D reporting that their ownership in Werewolf Therapeutics common stock has fallen below the five percent threshold.
The reporting group now beneficially owns 1,985,541 shares, or 4.1% of the common stock, based on 48,596,817 shares outstanding as of May 1, 2026. Most of these shares, 1,853,646, are held by RA Capital Healthcare Fund, L.P., with an additional 131,895 shares held by RA Capital Nexus Fund II, L.P.
The funds recently executed several open market sales between June 29 and July 2, 2026, at weighted average prices ranging from $0.30 to $0.36 per share. The filing states the group ceased to be beneficial owners of more than five percent of Werewolf’s common stock on June 30, 2026, an important regulatory threshold for large shareholders.